Daniel Vt Catenacci News Today

Summer is heading for its traditional close at Labor Day as many have either returned to school or are finalizing their plans. The Commission…

A former University of Chicago professor who pled guilty to insider trading with information about a positive cancer drug trial he was involved in won't serve prison time after an Illinois federal judge sentenced him Wednesday to time served and a year of supervised release.

Eli Lilly Accused of Defrauding Government in $60 Million Qui Tam Suit - In a qui tam suit alleging that Eli Lilly and Co. (“Eli Lilly”) violated the False Claims Act, a...

A physician and professor at the University of Chicago entered a plea of not guilty Tuesday to charges that he traded on inside information from Five Prime Therapeutics Inc. ahead of the publication of positive results of a drug trial for its leading cancer drug bemarituzumab.

Dr Daniel Catenacci, the lead investigator in a clinical trial for the drug bemarituzumab, has been charged with violating the antifraud provisions of the federal securities laws.

U.S. authorities have charged a Chicago doctor with insider trading, accusing him of using nonpublic information about drug trial results to reap illicit profits from buying shares of a...

A physician and professor at the University of Chicago has been accused of trading on inside information from Five Prime Therapeutics Inc. ahead of the publication of positive results of a drug trial for its leading cancer drug bemarituzumab, prosecutors said Monday.

WASHINGTON (Reuters) - The U.S. Securities and Exchange Commission (SEC) on Monday said it charged a Chicago medical school professor with insider tra...

WASHINGTON (Reuters) - The U.S. Securities and Exchange Commission (SEC) on Monday said it charged a Chicago medical school professor with insider tra...

<p><span>The Securities and Exchange Commission today announced charges against Daniel V.T. Catenacci for insider trading in the securities of biotechnology company Five Prime Therapeutics, Inc. in advance of the company’s November 10, 2020 announcement that it had achieved positive drug trial results for its flagship cancer drug Bemarituzumab.</span></p>